Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Price Increases Accelerate: ‘Political Opportunism’ In A Return To Business As Usual?

Executive Summary

Advocates for drug pricing reform don’t have much in the way of price increases to complain about at the moment – but they argue that the price hikes they are seeing suggest a growing confidence among manufacturers that the threat of drug pricing reform is subsiding.

You may also be interested in...



Democratic Drug Pricing Push: Starting And Ending With Insulin?

When the Democratic party regained control of the US House of Representatives in 2019, their push to enact comprehensive drug pricing legislation began with a hearing on insulin. After four years, it might be ending with insulin as the sole focus after all.

Biden’s State Of The Union Will Mention Drug Prices, But Not Outline Any New Plans

President’s address to Congress expected to urge action on the provisions in the stalled Build Back Better legislation as part of a call to address inflation – though whether the speech will include the “i-word” remains unclear. PhRMA emphasizes that drug prices are stable.

2022: The End Of The US Price Negotiation Debate?

The Democratic party has been advocating for Medicare drug price negotiation authority in the US for almost two decades. The coming year may see it finally happen – or it might mean the issue is gone for good.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel